ADA Updates: Obesity Drug Treatment & Long-Term Management Guidance
The landscape of obesity treatment is evolving rapidly, and a new chapter in the American Diabetes Association’s (ADA) Standards of Care in Overweight and Obesity reflects that shift, placing a strong emphasis on individualized, patient-centered approaches to pharmacologic treatment. Published in January in Diabetes, Obesity, and Cardiometabolic CARE, the guidance aims to equip healthcare professionals with the tools to navigate a growing arsenal of medications and integrate them effectively into comprehensive care plans.
Tailoring Treatment to the Individual
The updated standards acknowledge that obesity is a complex, chronic disease, and a one-size-fits-all approach simply won’t work. Kimberly A. Gudzune, MD, MPH, chief medical officer for the American Board of Obesity Medicine Foundation and chair of the ADA’s professional practice committee for obesity, emphasized the importance of a detailed initial evaluation and ongoing monitoring. “Each patient has such different contexts, so it’s difficult to say this one drug should be used for everyone,” she told Healio. “Letting prescribers realize that they have multiple options is important in thinking of balance.”
This individualized approach begins with a thorough discussion of patient goals, extending beyond simply lowering HbA1c or achieving weight loss. Recognizing “nonscale victories” and addressing individual motivations are crucial components of successful treatment. Healthcare professionals are encouraged to have open conversations about expectations, potential side effects, and the role of lifestyle interventions alongside medication.
Pharmacotherapy and Cardiometabolic Conditions
The new guidance details all FDA-approved obesity medications, providing insights into which drugs may be most appropriate for patients with various cardiometabolic conditions. Here’s particularly relevant given the increasing recognition of the interconnectedness between obesity and conditions like type 2 diabetes, heart disease, and non-alcoholic fatty liver disease. The chapter too offers guidance on implementing lifestyle interventions – nutritional changes and increased physical activity – in conjunction with pharmacotherapy.
The emergence of incretin-based drugs has significantly altered the treatment landscape, and the ADA standards address these newer therapies. However, Gudzune cautions against viewing medication as a standalone solution. “These medications are, designed to be used with a lifestyle treatment plan. They don’t replace lifestyle intervention,” she explained. Muscle strengthening activity is also highlighted as a key component of any weight reduction plan, helping to preserve lean mass and improve overall health.
The Importance of Nutritional Support
The guidance underscores the critical role of nutrition in obesity treatment. Medications can facilitate address challenges like constant hunger and cravings, making it easier for patients to adhere to dietary recommendations. However, it’s equally important to ensure adequate nutritional intake, particularly protein, fiber, and essential vitamins and minerals. The standards acknowledge that appetite suppression can sometimes lead to inadequate nutrition, necessitating careful monitoring and potential supplementation.
Gudzune also addressed the phenomenon of “food noise” – intense cravings and preoccupation with food – which can be particularly challenging for individuals with obesity. Medications can help mitigate food noise, but a comprehensive nutritional plan remains essential.
Long-Term Management: A Chronic Disease Approach
A significant shift in the updated standards is the recommendation for continued use of obesity medications to maintain health benefits. This reflects a growing understanding of obesity as a chronic disease, similar to hypertension or diabetes. Studies have shown that discontinuing medication often leads to weight regain and a return of associated health problems.
“Part of this is realizing that obesity is a chronic disease,” Gudzune stated. “When you’re prescribed a medication for your blood pressure, when your blood pressure goes down, we don’t say, ‘You don’t require it anymore because your blood pressure is controlled.’ Similar to hypertension being a chronic disease, obesity is also a chronic disease.”
However, the guidance also acknowledges that discontinuation rates are high, often due to prescriber behavior (prematurely stopping medication) and patient factors (cost, insurance coverage). Gudzune emphasized the need to reframe the discussion around obesity treatment as a long-term investment, and to address barriers to access and affordability.
What’s Next for Obesity Treatment?
The ADA’s updated Standards of Care represent a significant step forward in the management of obesity. Ongoing research will continue to refine our understanding of the optimal use of pharmacotherapy and the interplay between medication and lifestyle interventions. Further studies are needed to determine whether some individuals can safely discontinue medication after achieving sustained weight loss, and to address the challenges of long-term adherence and affordability. Policymakers also have a role to play in ensuring equitable access to these potentially life-changing treatments. The World Health Organization’s recent conditional recommendation for the use of GLP-1s in obesity treatment further underscores the growing global recognition of obesity as a serious public health concern.
Kimberly A. Gudzune, MD, MPH, can be reached at [email protected] or on LinkedIn @KimberlyGudzune.